Initial results of a phase i trial of continuous infusion SR 2508 (etanidazole): A radiation therapy oncology group study

C. Norman Coleman, R. N. Lisa Noll, Anthony E. Howes, Jay R. Harris, Jehane Zakar, Robert A. Kramer

Research output: Contribution to journalArticle


To exploit both the oxygen-mimetic and "pre-incubation" or continuous exposure effects of the 2-nitroimidazole radiosensitizers, we are conducting a Phase I trial of continuous infusion SR 2508 for patients receiving brachytherapy. Following the administration of a loading dose of 2 g/m2, SR 2508 is administered by continuous infusion for 48 hr. Twenty-one patients have completed treatment. The initial total dose was 8 g/m2 with patients currently receiving 15 g/m2. No toxicity has been observed. At the higher doses the steady-state plasma concentrations have been between 50 and 70 μg/ml. It is not yet known whether or not hypoxic sensitizers will be of benefit clinically, and if so, when during a course of treatment is the optimal time to use them. Given the lack of toxicity and plasma concentrations achievable with continuous infusion, future studies will be conducted using SR 2508 during both the external beam and brachytherapy aspects of treatment.

Original languageEnglish (US)
Pages (from-to)1085-1087
Number of pages3
JournalInternational Journal of Radiation Oncology, Biology, Physics
Issue number4
Publication statusPublished - 1989
Externally publishedYes



  • Brachytherapy
  • Continuous infusion chemotherapy
  • Etanidazole
  • Hypoxic cell sensitizers
  • SR 2508

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this